Tumor-Derived Extracellular Vesicle Detection Using β-Sheet Signatures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing EV-based cancer diagnostic assays are either subtype-specific or vulnerable to high background signals, making them unreliable for noninvasive cancer detection.
Innovation Solution
Utilize the β-sheet richness of tumor-derived extracellular vesicles (EVs) as a collective attribute for discrimination, employing methods like circular dichroism, FT-IR spectroscopy, and fluorescence staining, integrated with immunoprecipitation and Thioflavin T staining to develop the EvIPThT assay.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If single cancer-associated marker or marker signatures are used in EV-based diagnostic assays, then the assays can be subtype-specific, but they are vulnerable to high background signals and masking effects
Solution Approach 1:
The patent combines multiple single-marker assays into a multi-marker signature assay that evaluates EV contents as a collective attribute. By merging several cancer-associated markers into a composite signature, the assay achieves better discriminatory power while the collective evaluation reduces the impact of high background signals that mask individual markers.
Solution Approach 2:
The patent creates a composite biomarker signature by integrating multiple markers into a unified diagnostic criterion. This composite approach evaluates the combined presence and characteristics of multiple markers rather than relying on single markers, thereby improving measurement precision and reducing vulnerability to background interference.
2Measurement precision
If multiple markers are combined into a signature assay, then the discriminatory power improves, but the assay complexity increases
Solution Approach 1:
The patent develops a multi-functional assay platform that can evaluate multiple cancer-associated markers simultaneously using a unified methodology. The assay integrates immunoprecipitation, fluorescence labeling, and spectral analysis into a single workflow that handles multiple markers without requiring separate assays for each marker, thereby improving discriminatory power while managing complexity through standardization.
Solution Approach 2:
The patent changes the evaluation parameter from individual marker detection to collective signature evaluation. By shifting the measurement focus to the combined characteristics of multiple markers (β-sheet richness as a collective attribute), the assay achieves enhanced discriminatory power while using a standardized measurement approach that controls complexity.
3Measurement precision
If β-sheet richness is used as a collective attribute for EV evaluation, then the ability to discriminate malignant from nonmalignant EVs improves, but the measurement and analysis difficulty increases
Solution Approach 1:
The patent replaces complex mechanical separation and characterization methods with fluorescence spectroscopy-based detection. By using fluorescence labeling compounds that bind to β-sheet structures and measuring their spectral characteristics, the assay simplifies the detection process while maintaining high discriminatory power for distinguishing malignant from nonmalignant EVs.
Solution Approach 2:
The patent utilizes fluorescence labeling compounds that exhibit characteristic spectral signals when bound to β-sheet structures. The measurement of fluorescence intensity and spectral characteristics provides a simplified readout for β-sheet richness, transforming a complex structural analysis into an optical measurement that is easier to perform and interpret.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The EvIPThT assay effectively distinguishes between malignant and nonmalignant samples with high discriminatory power, correlating with prognosis biomarkers and showing independence from treatment effects, thus promising as a cancer screening tool.
Implementation Method 1
combining an antibody and a sample under conditions suitable for formation of antigen-antibody complexes, where the antibody reacts with an extracellular vesicle tumor-specific surface antigen
Implementation Method 2
exposing the tumor-derived extracellular vesicles to a compound that binds beta-sheet structures. The compound that binds beta-sheet structures can be Thioflavin T or Congo red
Implementation Method 3
circular dichroism, Fourier transform infrared spectroscopy, fluorescence staining assays
Implementation Method 4
circular dichroism, Fourier transform infrared spectroscopy, fluorescence staining assays
Implementation Method 5
fluorescence staining assays
Data Source
AI summary
Provided are methods for identifying tumor-derived extracellular vesicles. The methods can include combining an antibody and a sample under conditions suitable for formation of antigen-antibody complexes with tumor-derived extracellular vesicles. The methods also include exposing the tumor-derived extracellular vesicles to a compound that binds beta-sheet structures, and determining if there is a change in binding of the compound to the extracellular vesicles compared to one or more controls.